Chris JacobsSell
Inovio Pharmaceuticals, Inc. · Transaction Sep 8, 2020 · Filed Nov 6, 2020 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · INO
-3.03% · -$0.0300 · Vol 3.2M
Market closed · last close 4:00 PM ET · price as of 19:58:01 ET
Inovio Pharmaceuticals Inc
Biotechnology
$1.12
Follow $INO
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $INO by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredThu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET · INO
MethodologyINO
Inovio Pharmaceuticals Inc
Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
56/ 100
Veridion Score
Middle range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is INO moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Inovio Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
1998
Employees
112
Country
US
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$1.17
Day high
$1.18
Day low
$1.08
Previous close
$1.16
52W high
$2.65
-57.74% from high
52W low
$0.6560
23% of range
Market cap
$119.4M
EPS
$-1.1699
Beta
-0.74
Shares out
103.4M
Volume
3.2M
1.11× rel vol
Avg volume
2.9M
VWAP
$1.11
Price history computed in-house
1W
-3.45%
1M
-15.15%
3M
-5.08%
1Y
-57.74%
YTD
-35.63%
SMA 50 $1.12 · above
SMA 200 $1.33 · below
52W position 23%
INO overview
Related filings and maps
Public disclosures
Congress activity in INO
1 filers · 0 buys · 1 sells (0 labeled S (partial)) · Sep 8, 2020 to Sep 8, 2020 · House 1 / Senate 0
All available history · Latest 1 of 1 lines · Read 2026-10-09T03:13:30.953Z
Official filing ↗
Federal contracts
INO contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for INO in this window.
Lobbying spend
INO lobbying filings, year to date.
Registered lobbying filings matched to Inovio Pharmaceuticals Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for INO in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for INO.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.